Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib for High Risk NMIBC Unresponsive to BCG (BLASST-3)
NCT04040725Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rogaratinib in non-muscle-invasive bladder cancer (NMIBC), sponsored by Dana-Farber Cancer Institute. Planned start Nov 2019; status: withdrawn.
02
Drugs
rogaratinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04040725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040725.